Angiotensin-(1-7) Promotes Resolution of Neutrophilic Inflammation in a Model of Antigen-Induced Arthritis in Mice

Lívia C. Barroso¹†, Giselle S. Magalhaes²†, Izabela Galvão¹, Alessandra C. Reis³, Daniella G. Souza⁴, Lirlândia P. Sousa⁵, Robson A. S. Santos², Maria Jose Campagnole-Santos², Vanessa Pinho³ and Mauro Martins Teixeira¹*

¹Department of Biochemistry and Immunology, Biological Sciences Institute, Federal University of Minas Gerais, Belo Horizonte, Brazil; ²Department of Physiology and Biophysics, Biological Sciences Institute, Federal University of Minas Gerais, Belo Horizonte, Brazil; ³Department of Morphology, Biological Sciences Institute, Federal University of Minas Gerais, Belo Horizonte, Brazil; ⁴Department of Microbiology, Biological Sciences Institute, Federal University of Minas Gerais, Belo Horizonte, Brazil; ⁵Department of Clinical and Toxicological Analysis, School of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil

Defective resolution of inflammation may be crucial for the initiation and development of chronic inflammatory diseases, such as arthritis. Therefore, it has been suggested that therapeutic strategies based on molecules that facilitate inflammation resolution present great potential for the treatment of chronic inflammatory diseases. In this study, we investigated the effects and role of angiotensin-(1-7) [Ang-(1-7)] in driving resolution of neutrophilic inflammation in a model of arthritis. For this purpose, male C57BL/6 mice were subjected to antigen-induced arthritis and treated with Ang-(1-7) at the peak of the inflammatory process. Analysis of the number of inflammatory cells, apoptosis, and immunofluorescence for NF-κB was performed in the exudate collected from the knee cavity. Neutrophil accumulation in periarticular tissue was measured by assaying myeloperoxidase activity. Apoptosis of human neutrophil after treatment with Ang-(1-7) was evaluated morphologically and by flow cytometry, and NF-κB phosphorylation by immunofluorescence. Efferocytosis was evaluated in vivo. Therapeutic treatment with Ang-(1-7) at the peak of inflammation promoted resolution, an effect associated with caspase-dependent neutrophils apoptosis and NF-κB inhibition. Importantly, Ang-(1-7) was also able to induce apoptosis of human neutrophils, an effect associated with NF-κB inhibition. The pro-resolving effects of Ang-(1-7) were inhibited by the Mas receptor antagonist A779. Finally, we showed that Ang-(1-7) increased the efferocytic ability of murine macrophages. Our results clearly demonstrate that Ang-(1-7) resolves neutrophilic inflammation in vivo acting in two key step of resolution: apoptosis of neutrophils and their removal by efferocytosis. Ang-(1-7) is a novel mediator of resolution of inflammation.

Keywords: resolution of inflammation, angiotensin (1-7), apoptosis, neutrophils, efferocytosis
INTRODUCTION

Rheumatoid arthritis (RA) is an inflammatory autoimmune disease characterized by chronic and deforming destructive arthritis accompanied by systemic dysfunctions (1). RA affects approximately 1% of the adult population in the world (2). The cost of RA is very high, associated with decreased productivity and impact on quality of life (3). Neutrophils are the most abundant leukocytes recruited to the joints of patients with active RA (4, 5) and can contribute to aggravate articular inflammation and tissue damage (6).

In chronic inflammatory diseases, persistent inflammation contributes to tissue damage and the consequent loss of organ function (7, 8). Persistent inflammation may be secondary to the constant influx of leukocytes due to the continued production of inflammatory mediators (9). However, recent evidences suggest that the inability to resolve ongoing inflammation may be a major contributor to persistent inflammation. Resolution of inflammation is an active process, finely tuned by mediators that (i) prevent excessive trafficking of leukocytes to the site of damage (10); (ii) shutdown intracellular signaling molecules associated with cytokine production and leukocyte survival (11); (iii) induce apoptosis of recruited inflammatory cells; and (iv) promote clearance of apoptotic cells (especially by macrophages) by a process named efferocytosis (12). Altogether, these actions will allow the cessation of inflammation and reestablishment of tissue homeostasis (13, 14). In RA, reduced neutrophil apoptosis correlate positively with disease severity (15, 16).

Angiotensin-(1-7) [Ang-(1-7)] is a peptide of the renin-angiotensin system mainly known to be involved with the control of cardiovascular, renal, and vascular functions. This peptide gained interest in recent years due to its anti-inflammatory and anti-fibrotic effects in different acute and chronic inflammatory conditions, including asthma (17), dyslipidemia (18), renal injury (19, 20), and myocardial infarction (21). Ang-(1–7) is mostly synthesized by ACE2 (22, 23), and the majority of its biological actions are mediated through the G-coupled Mas receptor (24), counterbalancing the effects of the ECA/Ang II/AT1 receptor pathway in different pathophysiologic processes.

In previous studies, our group demonstrated that preventive administration of Ang-(1-7) or a synthetic analog, AVE0991, decreased rolling and adhesion of leukocytes to the microvascular endothelium at inflamed joints in a model of antigen-induced arthritis (AIA) (25). The inhibition of leukocyte interaction with endothelial cells was associated with decreased neutrophil influx into the joints, cytokine release inhibition, and improvement of joint hypernociception (25). In this study, we investigated the effects of therapeutic administration of Ang-(1-7) in driving resolution of neutrophilic inflammation in a model of arthritis. Our results demonstrate marked and novel pro-resolving actions of Ang-(1-7) in vivo in two key steps of the resolution process—apoptosis and efferocytosis.

MATERIALS AND METHODS

Animals

Eight to ten weeks old male C57Bl/6 mice (20–25 g) were obtained from the animal facility of our institution. Animals were maintained under temperature-controlled condition with an artificial 12 h light–dark cycle with free access to chow and water. The study was approved by the local Animal Ethics Committee (CETEA 192/2012).

AIA in Mice

To induce arthritis, animals were immunized with an intradermal injection of 100 µg of methylated bovine albumin (mBSA, Sigma, St. Louis, MO, USA), emulsified in 500 µg of Freund’s complete adjuvant (CFA, Sigma) at the base of the tail (day 0). Two weeks after immunization, antigen challenge was performed by injection of 10 µg of mBSA diluted in 10 µl of sterile saline into the left joint. As control group received intra-articular injection of PBS (10 µl) into the same site. Mice were treated with an intra-articular injection (10 µl) of 100 ng of Ang-(1-7) (Bachem, Torrance, CA, USA), Mas antagonist, A779 [D-Ala7-Ang-(1-7), 200 ng/cavity; Bachem, Torrance, CA, USA], or the vehicle (NaCl 0.9%) 12 h after antigen challenge (26). All surgical procedures were performed under ketamine and xylazyn anesthesia (150 and 10 mg/kg, respectively) followed by euthanasia.

Tissue Neutrophil Infiltration

The extent of neutrophil accumulation in periarticular tissue was measured by assaying myeloperoxidase (MPO) activity, as described elsewhere (27). Results were expressed as the relative number of neutrophils per milligram of synovial tissue. Intra-articular neutrophil infiltration 24 h after antigen challenge was measured in the liquid collected from the knee cavity after been washed twice with 10 µl BSA. The total number of leukocytes was counted in Neubauer chamber after staining with Türk’s solution. Differential leukocyte counts were obtained after staining of Cytospin slides with May–Grünewald–Giemsa using standard morphologic criteria.

Calculation of Resolution Indices

We quantified the resolution indices as described (28, 29). Murine synovial fluid was collected at 12, 24, 36, 48, and 72 h after challenge with mBSA. The treatment with Ang-(1-7) was performed at the peak of inflammation, 12 h after the challenge. The number of PMN and mononuclear cells was determined by total and differential leukocyte counting. The resolution of acute inflammation were defined in quantitative terms by the following resolution indices: (1) magnitude (Ψmax and Tmax); Ψmax (maximal PMN), Tmax (time point when PMN numbers reach maximum); (2) duration (T50, T90); T50 (time point when PMN numbers reduce to 50% of maximum); and (3) R, (the interval between Tmin and T90; when 50% of PMNs are lost from the synovial fluid) (28).

Assessment of Leukocyte Apoptosis

Apoptosis was assessed morphologically, as reported previously (13, 30, 31). Briefly, 5 × 10⁴ cells collected 24 h after antigen challenge were cyto-centrifuged, fixed and stained with May–Grünewald–Giemsa. Cells were counted using oil immersion microscopy (×100 objective) to determine the proportion of cells with distinctive apoptotic morphology, i.e., cells that presented chromatin condensation, nuclear fragmentation, and formation of apoptotic bodies, both out or inside macrophages. At least 500
cells were counted/slide and the results expressed as percentage of cells with apoptotic morphology. Assessment of apoptosis was also performed by flow cytometry using FITC-labeled Annexin-V (ApoDETECT Annexin V-FITC kit; Invitrogen, Carlsbad, CA, USA) and PI as an index of loss of nuclear membrane integrity.

**Isolation of Neutrophils by Density Gradient Centrifugation**

Blood from healthy human donors (Ethics Committee of the Universidade Federal de Minas Gerais, Brazil—Institutional Review Board Project number 0319.0.203.000-11) was collected in EDTA tubes, and diluted 1:1 with RPMI. Human neutrophils (PMNs) were separated by gradient centrifugation over Histopaque-1119 and Histopaque-1077 (Sigma-Aldrich®). To avoid mixing the two densities, which will preclude cell separation during centrifugation, blood was centrifuged for 30 min at 2,000 rpm at 25°C without brake. Neutrophils were collected at the interface of the Histopaque-1119 and Histopaque-1077 layers. After wash with PBS, viable cells were counted. Neutrophils were >95% viable and >5% pure.

**Confocal Microscopy**

Cells of joint lavage or PMN were centrifuged, at 1,200 rpm for 5 min at 4°C, and the pellet was resuspended in PBS, and total cell counts were performed. From the total number were taken 5 x 10^5 cells to perform cyto centrifugation (Cytospin; Shandon Lipshaw Inc., Pittsburgh, PA, USA) in coverslip slides. Next, cells were fixed with 4% paraformaldehyde for 15 min and washed three times. Fc Block (CD16/32, BD Biosciences) was added for 30 min to block unspecific binding of antibody. To perform intracellular staining cells coverslips were permeabilized for 30 min (Perm Wash, BD Bioscience; 1:12 in PBS-BSA 1%) and incubated with the antibody overnight. For extracellular staining, antibodies were added. Finally, the coverslips were processed with Fluoromount (Aldrich Sigma, USA) for analysis. Images were obtained in a Nikon Eclipse Ti microscope with laser confocal C2, equipped with three different lasers (excitation 405, 488, and 543 nm) and emission filter 450/50 nm (channel 1), 515/30 nm (channel 2), and 584/50 nm (channel 3). The fluorescence intensity was measured using a 6.3 Velocity software (Perkin-Elmer, USA), and the fluorescence profile was assessed using Image J (NIH, USA). The antibodies used were p65 Alexa Fluor 488 (Cell signaling; 1:100), DAPI (Cell signaling; 1:100), Siglec-F (Santa Cruz, CA, USA; 1: 100) and MAS (Alomone, 1:100) diluted in permeabilization solution (wash-perm; BD Bioscience).

**Efferocytosis Assay In Vivo**

Human neutrophils (PMNs) were isolated from peripheral venous blood drawn from healthy volunteers, after informed written consent, as described previously (32). Briefly, PMNs were separated as described earlier and plated at 5 x 10^6 cells/well. Apoptosis (>80%) was induced by staurosporine (10 µM), Ang-(1-7) (100 nM) or staurosporine (10 µM), and Ang-(1-7) (100 nM) by culturing the neutrophils in complete RPMI 1640 for 1 h at 37°C in 5% CO2 atmosphere. 4 x 10^6 apoptotic PMNs were injected intraperitoneally into mice bearing a 72 h peritonitis elicited by 0.1 mg of zymosan. When indicated, mice were treated with different doses of Ang-(1-7) (0.1–3.0 µg/mice) 30 min before the injection of apoptotic cells. Animals were killed after 90 min later, and exudates were collected for morphologic analysis (33, 34).

**Data Statistical Analysis**

All results are expressed as mean ± SEM. Comparisons among three or more groups were performed by one-way ANOVA followed by Newman–Keuls post hoc test. Significance between two groups was assessed by Student’s t-test. All analysis and graphics were performed with GraphPad Prism software (version 5.0; La Jolla, CA, USA). The level of significance was set to p ≤ 0.05.

**RESULTS**

**Ang-(1-7) Resolves Neutrophilic Inflammation in Arthritis**

**Ang-(1-7) Promotes Resolution by Inducing Neutrophil Apoptosis**

We used a well-established model of AIA in mice (Figure 1) to evaluate the effect of Ang-(1-7) on inflammatory responses (26) and resolution (28). In this model of AIA, injection of antigen in the knee joints of immunized C57BL/6 mice induced significant neutrophil influx that peaked from 12 to 24 h after the challenge with mBSA (15). We have previously shown that treatment with Ang-(1-7) before antigen challenge prevented neutrophil influx (25). Herein, we investigated the effect of local administration of Ang-(1-7) on the kinetics of neutrophil influx in AIA. Mice received challenge injection of mBSA, and 12 h later, an articular Ang-(1-7) injection, and cells were collected at 12, 24, 36, 48, and 72 h after challenge. The treatment of mice with Ang-(1-7) shortened Rₐ(AIA) ~ 25 h; Rₐ(Ang-(1-7)) ~ 9 h. Therefore, Ang-(1-7) treatment given 12 h after antigen challenge anticipated inflammatory resolution by 16 h (Figure 1A). In addition, the treatment with Ang-(1-7) at the peak of the inflammatory response decreased neutrophil accumulation in the synovial cavity (Figure 1B) and in periarticular tissues (Figure 1C). There was also increase in the percentage of apoptotic neutrophils (Figure 1D). The increase in the percentage of apoptotic neutrophils was confirmed by experiments evaluating the expression of Annexin-V on the surface of neutrophils (Figure 1E).

Systemic administration of Ang-(1-7) (Figures S1A,D in Supplementary Material) as an inclusion compound containing Ang-(1-7) [HP]βCD-Ang-(1-7); Figures S1B,E in Supplementary Material] or local treatment with Ang-(1-7) (Figures S1C,F in Supplementary Material) at the peak of inflammation decreased the number of neutrophils in the synovial cavity and periarticular tissues. Both local and systemic Ang-(1-7) administration were equally effective and maximal inhibition occurred at 100 ng/cavity. Consistent with the latter findings, administration of the broad-spectrum caspase inhibitor, zVAD-FMK, prevented the ability of Ang-(1-7) to resolve neutrophilic inflammation and to induce apoptosis in this AIA model (Figures 1B–D). These data suggest that Ang-(1-7) promotes resolution of the inflammation by inducing caspase-dependent neutrophil apoptosis. A similar reduction was not observed in mononuclear cells (data not shown).
The Effects of Ang-(1-7) Are Mas-Dependent

Next, we investigated the role of the Mas receptor in mediating the pro-resolving activity of Ang-(1-7). In agreement with data shown in Figure 1, administration of Ang-(1-7) 12 h after antigen challenge decreased inflammation and promoted resolution of inflammation by decreasing neutrophil accumulation in the synovial cavity (Figure 2A) and increasing the percentage of neutrophil apoptosis (Figure 2B). Blockade of the Mas receptor by treatment with a selective receptor antagonist, A779, prevented the pro-resolving actions of Ang-(1-7) (Figures 2A,B).

We then assessed whether Ang-(1-7) had an endogenous effect on the resolution of AIA. To this end, we treated animals with A779 at 12 h after antigen challenge and natural resolution of neutrophil inflammation was followed till 72 h after challenge. As it can be seen in Figure 2C, the number of neutrophils in the joint was greater in mice treated with A779 at 48 h, but not 72 h, after challenge. Therefore, A779 was able to delay the kinetics of natural resolution of AIA, but eventually resolution occurred both in control and drug-treated mice (Figure 2C). There were no significant changes in number of apoptotic neutrophils at the time points examined (Figure 2D).

Ang-(1-7) Induced Apoptosis in Human Neutrophils

Next, we explored whether Ang-(1-7) would also induce apoptosis in human neutrophils. Neutrophils undergo quick spontaneous apoptosis in vitro (Figure 3). Treatment with Ang-(1-7) induced...
Figure 2. The Mas antagonist, A779, reverses the pro-resolution effect of angiotensin-(1-7) [Ang-(1-7)] in a model of arthritis in mice. (A,B) The number of neutrophils and the percentage of apoptotic neutrophils in the synovial cavity, respectively, in antigen-induced arthritis (AIA) mice 12 h after treatment with Ang-(1-7) alone or Ang-(1-7) and A779. (C,D) The number of neutrophils and the percentage of apoptotic neutrophils in the synovial cavity, respectively, in AIA mice 48 and 72 h after challenge treated with A779. Bars show the mean ± SEM from eight mice per group. *p ≤ 0.05 as compared with PBS-control group; #p ≤ 0.05 as compared with AIA group (one-way ANOVA followed by Newman-Keuls test).

Ang-(1-7)-Induced Resolution In Vivo and Apoptosis of Human Neutrophils In Vitro Are Associated with Decreased Phosphorylation of p65 NF-κB

The transcription factor NF-κB is known to contribute to the survival of neutrophils in vivo (35). As it can be seen in Figure 4, treatment with Ang-(1-7) was associated with decrease in NF-κB activation in neutrophils recruited to the synovial cavity of the mice, as seen by the decreased phosphorylation of this transcription factor (Figures 4A,B). Interestingly, treatment of human neutrophils with Ang-(1-7) decreased NF-κB activation (Figures 4C,D), an important survival factor for neutrophils (35). IkBα was evaluated by western blot to confirm the previous data. As seen in Figure S3 in Supplementary Material, treatment of human neutrophils with Ang-(1-7) for 2 h significantly decreased pIkBα expression. These results suggest that inhibition of NF-κB phosphorylation is a major target for the ability of Ang-(1-7) to induce apoptosis of neutrophils.

Ang-(1-7) Increases the Efferocytic Ability of Murine Macrophage

Leukocyte apoptosis and subsequent removal of apoptotic cells by phagocytes (efferocytosis) are crucial events for the resolution of inflammation (36). Our data showed that Ang-(1-7) promotes resolution by inducing leukocyte apoptosis. Next, experiments were performed to investigate the ability of Ang-(1-7) to regulate macrophage efferocytosis. To this end, apoptotic cells were injected in the peritoneal cavity of mice, their engulfment by zymosan-recruited peritoneal macrophages evaluated and presented as an efferocytosis index (33, 37, 38). At the time of injection, over 90% of neutrophils were apoptotic. In addition, at 72 h after zymosan injection, macrophages were the very predominant cell type in cavity. These results are in agreement with previous studies in the laboratory (38). Efferocytosis of apoptotic...
neutrophils by resident macrophages was evaluated 90 min after injection of apoptotic neutrophils in the mice peritoneal cavity of mice. Figure 5A shows that treatment with Ang-(1-7) (0.1, 0.3, 1, or 3 µg) significantly increased efferocytosis of apoptotic human neutrophils. Figure 5B shows representative images of efferocytosis in macrophage stimulated with Ang-(1-7). We also tested whether treatment of neutrophils themselves would modify their subsequent efferocytosis by macrophages. To this end, human neutrophils were treated with Ang-(1-7) (100 nM), staurosporine (10 µM), or both for 1 h, and efferocytosis of apoptotic neutrophils by resident macrophages evaluated 90 min after injection of apoptotic neutrophils. As seen in Figure 5C, treatment of neutrophils with Ang-(1-7) also increased their subsequent uptake by macrophages.

**DISCUSSION**

Resolution of inflammation is an active process that tempers inflammation. Resolution is associated with increased neutrophil apoptosis and their timely removal by macrophages and aims to restore tissue homeostasis (39). Defective resolution of inflammation is thought to be crucial for the initiation and development of chronic inflammatory diseases, including RA (15, 25). Therefore, it has been suggested that therapeutic strategies based on mechanisms or molecules that facilitate inflammation resolution present great potential for the treatment of chronic inflammatory diseases. In this study, we evaluated the effects and therapeutic potential of Ang-(1-7) administration in the context of inflammatory resolution in an animal model of arthritis. We demonstrated that treatment with Ang-(1-7) at the peak of inflammation, i.e., after the influx of cells: (i) reduced the accumulation of neutrophils in inflammatory sites; (ii) induced apoptosis of neutrophils; and (iii) increased macrophage efferocytosis, which is consistent with its pro-resolving activities. We also showed that the (iv) pro-resolving effects of Ang-(1-7) were Mas receptor dependent, as demonstrated by experiments with the Mas receptor antagonist, A779. Further, we showed that (v) Ang-(1-7) induced apoptosis of human neutrophils in vitro, and the resolution of neutrophilic inflammation was associated with a decrease of NF-κB phosphorylation. Altogether, these results demonstrate for the first time a marked pro-resolving action of Ang-(1-7) in a model of neutrophilic inflammation in vivo.

Previous studies have shown that preventive administration of Ang-(1-7) decreased inflammatory responses in various models of inflammation, including arthritis (17, 20, 25). The anti-inflammatory effects of Ang-(1-7) were Mas receptor-dependent and decreased inflammatory responses through the inhibition of leukocyte migration and cytokine expression (19, 40). Here, we demonstrate that therapeutic administration of Ang-(1-7), i.e., administration of Ang-(1-7) when inflammatory responses had already been established, resolved inflammation by inducing apoptosis and efferocytosis of leukocytes. Indeed, Ang-(1-7) resolved neutrophilic inflammation and induced apoptosis of neutrophils in a model of AIA. The effects of Ang-(1-7) were Mas...
receptor dependent and were followed by inhibition of NF-κB and caspase activation. Of note, we could observe the therapeutic action of Ang-(1-7) when it was given locally or systemically. Indeed, pro-resolving actions were resolved when Ang-(1-7) was given as an inclusion with cyclodextrin by the oral route, suggesting that activation of this pathway may eventually be exploited for the treatment of patients with RA.

Activation of the PI3K/AKT/NF-κB axis is a major survival pathway of leukocytes, including neutrophils (15, 31). Thus, inhibiting these pathways may result in apoptosis of leukocytes and resolution of inflammation. Indeed, we have previously shown that the resolution of established inflammation was associated with the blockade of NF-κB pathway (15). Furthermore, pro-resolutive molecules, such as Annexin-A1, induce leukocyte apoptosis and resolution of inflammation in vivo in part by regulating the activity of NF-κB (13). Our data clearly show that Ang-(1-7) decreases phosphorylation of NF-κB pathway, an effect that may partially explain the ability of this peptide to resolve neutrophilic inflammation. These inhibitory effects of Ang-(1-7) on the NF-κB pathway have been reported by others in different systems. For example, Ang-(1-7) decreased ovalbumin-induced perivascular and peribronchial inflammation, fibrosis, and goblet cell hyper/metaplasia, an effect that was associated with inhibition of IκB-α phosphorylation (41). Similarly, infusion of Ang-(1-7) significantly reduced infarct volume, improved neurological deficits, and suppressed NF-κB activity in a model of permanent cerebral ischemia (42). In another study, the ACE2/Ang-(1-7)/Mas axis played a crucial role in preventing LPS-induced apoptosis and inflammation of PMVECs by inhibiting the JNK/NF-κB pathways (43). Further studies are underway in our laboratories to unravel downstream mechanisms by which Mas receptor activation shuts down the NF-κB pathway and consequently induces apoptosis and resolution of inflammation.

The pro-resolving effects of Ang-(1-7) administration at the peak of inflammation were clearly Mas receptor dependent, since administration of A779 antagonist reversed these effects. Our data also revealed that treatment of arthritic mice with A779 alone delayed the natural resolution of neutrophilic inflammation. Indeed, although complete resolution was eventually attained, animals treated with A779 had significantly more neutrophils in the joint than vehicle-treated animals. These findings are in keeping with previous data derived from Mas-deficient mice in which neutrophilic inflammation was prolonged (25, 44). Although further studies are warranted, our results clearly indicate that endogenous production of Ang-(1-7) and activation of Mas receptors contribute to the normal resolution of inflammation.

For resolution of inflammation to occur in an orderly fashion and for tissue homeostasis to be restored, apoptotic cells must
be engulfed by tissue macrophages, a process referred to as efferocytosis. It is believed that agents that promote efferocytosis may contribute to the resolution of inflammation (45–47). For example, plasmin and plasminogen promote macrophage reprogramming and efferocytosis conduce to efficient resolution (38). Using a well-known approach to study efferocytosis in vivo (34, 48), our data demonstrate that treatment with Ang-(1-7) enhances apoptotic leukocyte clearance, suggesting that this effect may contribute to the pro-resolving effects of this mediator. The Mas receptor is known to be important factor for macrophage function during inflammation of the vascular system (49). However, to the best of our knowledge, this is the first demonstration that Ang-(1-7) increases apoptosis of neutrophils and efferocytosis by macrophages. Our data also showed that treatment of human neutrophils with Ang-(1-7) also lead to greater efferocytosis of apoptotic neutrophils by macrophages. The latter results suggest that part of the pro-efferocytic actions of Ang-(1-7) could be due to action of this molecule on neutrophils themselves. Further studies are necessary to see whether Ang-(1-7) may induce surface receptors on dying neutrophils that would favor their phagocytosis by macrophages. In any event, this is first study that demonstrates the direct capacity of Ang-(1-7) to induce efferocytosis by acting on macrophages or neutrophils themselves. In a dextran sulfate sodium colitis model, daily Ang-1-7 treatment induced significant apoptosis of immune cells (50). In the latter study, the effects of the Ang-(1-7) appeared to be secondary to the significant systemic anti-inflammatory action of the molecules. However, the latter data do concur with our findings. Indeed, direct induction of apoptosis on neutrophils and potentially other cell types could account for the observed effects of Ang-(1-7) in colitis (50).

At least one study (49) has shown that macrophages express the Mas receptor and that Mas receptor-deficient macrophages had an increase in gene expression of pro-inflammatory markers but a decrease in anti-inflammatory markers. Gene deficient macrophages also had enhanced migration and increased T-cell activation capacities (49). Interestingly, pharmacological Mas activation led to a shift toward M(IL-4 + IL-13)-polarized macrophages in vitro (49). As mentioned earlier, macrophages are crucial to efferocytose apoptotic neutrophils and provide anti-inflammatory signals to tissues. Further studies are needed to investigate in detail whether Ang-(1-7) could induce polarization of macrophages toward pro-resolving phenotypes. However, it is clear that Ang-(1-7) to induce macrophage efferocytosis (this study) and are capably of reprogramming macrophages away from pro-inflammatory phenotypes (49).

In conclusion, our data show that Ang-(1-7) treatment fulfills most of the criteria devised to consider a molecule as a
novel mediator of resolution of inflammation (8): (i) Ang-(1-7) reduced the accumulation of neutrophils into tissue, even after the influx of cells (shown here); (ii) Ang-(1-7) promoted apoptosis of neutrophils and increased their clearance by macrophages. Taken together with studies showing that (iii) Ang-(1-7) has well documented anti-inflammatory effects and induces polarization of macrophages away from activating phenotypes (49), our studies show that Ang-(1-7) has clear pro-resolving activities and endorse future research efforts aiming at the development of novel Ang-(1-7)-based pharmacological strategies to control, prevent, and even treat arthritis. Ang-(1-7) is a novel mediator of resolution of inflammation.

ETHICS STATEMENT

This study was carried out in accordance with the recommendations of Ethics Committee of Federal University of Minas Gerais-Brazil (Acceptance number: 0319.0.203.000-11).

AUTHOR CONTRIBUTIONS

GM and LB—study conception and design, data acquisition, analysis and interpretation, and drafting and revising the manuscript; DS and LS—data analysis and interpretation and revising the manuscript; IG and AR—data acquisition, analysis and interpretation, and manuscript revision; VP and RS—study conception and design, data analysis and interpretation, and drafting, editing, and revising the manuscript. All the authors approved the final version of manuscript.

ACKNOWLEDGMENTS

The authors are thankful to Denise Perez, Rayssa Andrade, and Ilma Marçal for technical assistance. This study was funded by the European Community’s Seventh Framework Programme under grant agreement HEALTH-F4-2011-281608. GM is postdoctorate researcher at the Graduation Program in Biological Sciences: Physiology and Pharmacology, UFMG and holds a CNPq fellowship. LB is a recipient of CAPES PhD fellowship at the Post-graduation Program in Biological Sciences: Biochemistry and Immunology, UFMG.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at http://www.frontiersin.org/article/10.3389/fimmu.2017.01596/full#supplementary-material.

FIGURE S1 | Therapeutic administration of angiotensin-(1-7) decreases neutrophil accumulation in the synovial cavity and periarticular tissues in a model of antigen-induced arthritis (AIA) in mice. Experimental protocol: On day 0, mice were immunized by injecting 10 µg of mBSA into each knee joint. Fourteen days later, arthritis was induced by an additional injection of 100 µg of mBSA into each joint (Challenge). At the peak of inflammation (12 h post-mBSA challenge, arrow), Ang-(1-7) was injected in peritoneal or given to gavage. Control mice were injected with 10 µL of PBS. At 24 h after challenge (12 h after treatment) the joints were washed. (A) Number of neutrophils present in the synovial cavity after systemic treatment with Ang-(1-7); (B) number of neutrophils present in the synovial cavity after systemic treatment with compound HPjICD + Ang-(1-7); (C) number of neutrophils present in the synovial cavity after local treatment with Ang-(1-7); (D) relative number of neutrophils present in the periarticular tissue, as determined by the activity of myeloperoxidase (MPO) after systemic treatment with Ang-(1-7); (E) relative number of neutrophils present in the periarticular tissue, as determined by the activity of MPO after systemic treatment with compound HPjICD + Ang-(1-7); (F) relative number of neutrophils present in the periarticular tissue, as determined by the activity of MPO after local treatment with Ang-(1-7). Bars show the mean ± SEM from eight mice per group.

FIGURE S2 | Expression of Mas receptor mRNA in human neutrophils. Mas receptor mRNA expression was assessed using real time-PCR. (A) Constitutive gene GAPDH (control) amplification blot; (B) constitutive gene melt curve GAPDH (control); (C) Mas receptor amplification blot; (D) Mas receptor melt curve.

FIGURE S3 | Angiotensin-(1-7) decreases pikBα expression. Human neutrophils were treated with Ang-(1-7) or PBS for 6 h and cells evaluated by Western blot analysis for pikBα. For loading control, membranes were reprobed with GAPDH. Blots are representative of three independent experiments using cells from different donors.

REFERENCES

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med (2011) 365:2205–19. doi:10.1056/NEJMr1004965
2. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature (2003) 423:356–61. doi:10.1038/nature01661
3. Dunlop DD, Manheim LM, Yelin EH, Song J, Chang RW. The costs of arthritis. Arthritis Rheum (2003) 49:101–13. doi:10.1002/art.10913
4. Kitis E, Weissmann G. The role of the neutrophil in rheumatoid arthritis. Clin Orthop Relat Res (1991) 265:63–72.
5. Kolaczewska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol (2013) 13:159–75. doi:10.1038/nri3399
6. Fattori V, Amaral FA, Veerri WA Jr. Neutrophils and arthritis: role in disease and pharmacological perspectives. Pharmacol Res (2016) 112:84–98. doi:10.1016/j.phrs.2016.01.027
7. Perez DA, Vago JP, Athayde RM, Reis AC, Teixeira MM, Sousa LP, et al. Switching off key signaling survival molecules to switch on the resolution of inflammation. Mediators Inflamm (2014) 2014:829851. doi:10.1155/2014/829851
8. Sugimoto MA, Sousa LP, Pinho V, Perrettì M, Teixeira MM. Resolution of inflammation: what controls its onset? Front Immunol (2016) 7:160. doi:10.3389/fimmu.2016.00160
9. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O’Neill LA, et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J (2007) 21:325–32. doi:10.1096/fj.06-72727rev
10. Serhan CN. The resolution of inflammation: the devil in the flask and in the details. FASEB J (2011) 25:1441–8. doi:10.1096/fj.11-0502fim
11. Milot E, Filep JG. Regulation of neutrophil survival/apoptosis by Mcl-1. ScientificWorldJournal (2011) 11:1948–62. doi:10.1100/2011/131539
12. Ariel A, Serhan CN. New lives given by cell death: macrophage differentiation following their encounter with apoptotic leukocytes during the
resolution of inflammation. *Front Immunol* (2012) 3:4. doi:10.3389/fimmu.2012.00004

13. Vago JP, Negueira CR, Tavares LP, Soriani FM, Lopes F, Russo RC, et al. Annexin A1 modulates natural and glucocorticoid-induced resolution of inflammation by enhancing neutrophil apoptosis. *J Leukoc Biol* (2012) 92:249–58. doi:10.1189/jlb.0112008

14. Vago JP, Tavares LP, Garcia CC, Lima KM, Perucci LO, Vieira EL, et al. The role and effects of glucocorticoid-induced leucine zipper in the context of inflammation resolution. *J Immunol* (2015) 194:8940–50. doi:10.4049/jimmunol.1401722

15. Lopes F, Coelho FM, Vieira EL, Prata PO, et al. Annexin (1-7) attenuates airway remodeling and hyperresponsiveness in a model of chronic allergic lung inflammation. *Br J Pharmacol* (2015) 172:2330–42. doi:10.1111/bph.13057

16. Felton JM, Lucas CD, Rossi AG, Dransfield E, Losinophils in the lung – modulating apoptosis and effecoryosis in airway inflammation. *Front Immunol* (2014) 5:302. doi:10.3389/fimmu.2014.00302

17. Magalhaes GS, Rodrigues-Machado MG, Motta-Santos D, Silva AR, Calari MV, Prata PO, et al. Annexin (1-7) attenuates airway remodelling and hyperresponsiveness in a model of chronic allergenic lung inflammation. *Br J Pharmacol* (2017) 172:2330–42. doi:10.1111/bph.13057

18. Santos RA, Ferreira AJ, Verano-Braga T, Bader M. Annexin-converting enzyme 2, annexin (1-7) and Mas: new players of the renin-angiotensin system. *J Endocrinol* (2013) 216:R1–17. doi:10.1530/JOE-12-0341

19. Barroso LC, Siqueira KD, Lima CX, Borges V, Bader M, Rachid M, et al. Renoprotective effects of AVE0991, a nonpeptide Mas receptor agonist, in experimental acute renal injury. *Int J Hypertens* (2012) 2012:808726. doi:10.1155/2012/808726

20. Silveira KD, Coelho FM, Vieira AT, Barroso LC, Queiroz-Junior CM, Costa CV, et al. Mechanisms of the anti-inflammatory actions of the annexin type 1 receptor antagonist losartan in experimental models of arthritis. *Peptides* (2013) 46:53–63. doi:10.1016/j.peptides.2013.05.012

21. Marques FD, Ferreira AJ, Sinisterra RD, Jacoby BA, Souza FB, Caliari MV, et al. An oral formulation of annexin (1-7) produces cardioprotective effects in infarcted and isoproterenol-treated rats. *Hypertension* (2011) 57:477–83. doi:10.1161/HYPERTENSIONAHA.110.167346

22. Donogheu M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. *J Immunol* (2000) 164:1663–7. doi:10.4049/jimmunol.164.1.1663

23. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human carbon monoxide accelerates resolution of inflammation via inhibition of PI3K/Akt and NF-kappaB. *Biochem Pharmacol* (2009) 78:396–405. doi:10.1016/j.bcp.2009.04.030

24. Greenlee-Wacker MC. Clearance of apoptotic neutrophils and resolution of inflammation. *J Immunol* (2012) 177:3537–70. doi:10.4049/jimmunol.1101245

25. Dalli J, Serhan C. Macrophage proresolving mediators – the when and where. *Microbiol Spectr* (2016) 4(4). doi:10.1128/microbiolspec.MCHD-0001-2014

26. Sugimoto MA, Ribeiro ALC, Costa BRC. Vago JP, Lima KM, Carneiro FS, et al. Plasmin and plasminogen induce macrophage reprogramming and regulate key steps of inflammation resolution via annexin A1. *Blood* (2017) 129:2896–907. doi:10.1182/blood-2016-09-742825

27. Norling LV, Serhan CN. Profiling in resolving inflammation exudates identifies novel anti-inflammatory and pro-resolving mediators and signals for termination. *J Intern Med* (2010) 268:15–24. doi:10.1111/j.1365-2958.2010.02235.x

28. Simoes e Silva AC, Silveira KD, Ferreira AJ, Teixeira MM, ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. *Br J Pharmacol* (2013) 169:477–92. doi:10.1111/bph.12159

29. El-Hashim AZ, Renno WM, Raghupathy R, Alhudo HT, Akhtar S, Benter IF. Annexin-(1-7) inhibits allergic inflammation, via the MAS1 receptor, through suppression of ERK1/2 and NF-kappaB-dependent pathways. *Br J Pharmacol* (2012) 166:1964–76. doi:10.1111/j.1476-5381.2012.01905.x

30. Jiang T, Gao L, Guo J, Lu J, Wang Y, Zhang Y. Suppressing inflammation by inhibiting the NF-kappaB pathway contributes to the neuroprotective effect of annexin-(1-7) in rats with permanent cerebral ischaemia. *Br J Pharmacol* (2013) 167:1520–32. doi:10.1111/j.1476-5381.2012.02105.x

31. Li Y, Cao Y, Zeng Z, Liang M, Xue Y, Xi C, et al. Annexin-converting enzyme 2/angiotensin-(1-7)/Mas axis prevents lipopolysaccharide-induced apoptosis of pulmonary microvascular endothelial cells by inhibiting JNK/NF-kappaB pathways. *Sci Rep* (2015) 5:8209. doi:10.1038/srep08209

32. Magalhaes GS, Rodrigues-Machado MG, Motta-Santos D, Alenina N, Bader M, Santos RA, et al. Chronic allergic pulmonary inflammation is aggravated in annexin-(1-7) Mas receptor knockout mice. *Am J Physiol Lung Cell Mol Physiol* (2016) 311:L1141–8. doi:10.1152/ajplil.00029.2016

33. Ortega-Gomez A, Perretti M, Soehnlein O. Resolution of inflammation: an integrated view. *EMBO Mol Med* (2013) 5:661–74. doi:10.1002/emmm.201202382

34. Khajah MA, Fateel MM, Ananthalakshmi KV, Luqmani YA. Anti-inflammatory action of annexin-1-7 in experimental colitis. *PLoS One* (2011) e105861. doi:10.1371/journal.pone.0105861

35. Korns D, Frasch SC, Fernandez-Boyanappali R, Henson PM, Bratton DL. Modulation of macrophage effecoryosis in inflammation. *Front Immunol* (2011) 2:57. doi:10.3389/fimmu.2011.00057

36. Montero-Melendez T, Patel HR, Seed M, Nielsen S, Jonassen TE, Perretti M. The melanocortin agonist AP214 exerts anti-inflammatory and proresolving properties. *Am J Pathol* (2011) 179:259–69. doi:10.1016/j.ajpath.2011.03.042

37. Hammer A, Yang G, Friedrich J, Kovacs A, Lee DH, Grave K, et al. Role of the receptor Mas in macrophage-mediated inflammation in vivo. *Proc Natl Acad Sci U S A* (2016) 113:14109–14. doi:10.1073/pnas.1621668113
50. Khajah MA, Fateel MM, Ananthalakshmi KV, Luqmani YA. Anti-inflammatory action of angiotensin 1-7 in experimental colitis may be mediated through modulation of serum cytokines/chemokines and immune cell functions. Dev Comp Immunol (2017) 74:200–8. doi:10.1016/j.dci.2017.05.005

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Barroso, Magalhães, Galvão, Reis, Sousa, Santos, Campagnole-Santos, Pinho and Teixeira. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.